SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
DateAugust 28, 2006_______________________
BIOTECH HOLDINGS LTD. _
(Exact name of Registrant as specified in its charter)
#160 - 3751 Shell Road, Richmond, British Columbia, Canada, V6X 2W2 _
(Address of principal executive offices)
Commission file number0-29108 _
(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F)
Form 20-F Yes Form 40-F No
(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)
No
Biotech Holdings Ltd.
Filed in this Form 6-K
Documents index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BIOTECH HOLDINGS LTD.
By: /s/ Robert Rieveley
Name: Robert Rieveley
Title: Chief Executive Officer
Date: August 28, 2006
BIOTECH HOLDINGS LTD.
FIRST QUARTER REPORT
June 30, 2006
Management^s Discussion and Analysis
This Management Discussion and Analysis (MD&A) has been prepared to provide a meaningful understanding of Biotech Holdings Ltd.^s ("the Company") operations, performance and financial condition for the 3 months ended June 30, 2006. The following should be read in conjunction with the Company^s unaudited interim consolidated financial statements as well and related notes therein that are prepared in accordance with generally accepted accounting principles in Canada ("Canadian GAAP"). Interim financial statements do not include all the disclosure requirements for annual financial statements and, accordingly, should also be read in conjunction with the Company audited financial statements dated March 31, 2006.
Forward-looking Information
This MD&A contains certain forward-looking statements and information relating to Biotech Holdings Ltd. that are based upon the beliefs of its management as well as assumptions made by and information currently available to the Company. When used in this document, the words "anticipate", "believe", "estimate" and "expect" and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements.
Date
The date of this MD&A is August 25, 2006.
Discussion of Operations and Financial Condition
Operating Results
Revenues from the sale of Sucanon in the 3 months ended June 30, 2006 were $48,621 which resulted in a Gross Profit of $24,724. The revenues in the same 3 month period ended June 30, 2005 were $123,411 and the Gross Profit was $80,785. While revenues increased over the $28,235 revenues in the quarter ended March 31, 2006, management is disappointed with the $74,790 (60.6%) decline in revenues in comparison with the prior year. The following factors contributed to the decline:
Operating expenses totaled $381,313 representing a $62,899 (14.1%) decrease from the $444,212 expenses incurred in the 3 months ended June 30, 2005.
Operating expenditures include $34,710 (2005 - $Nil) in product marketing costs. In the first 3 quarters of the fiscal year ended March 31, 2006, these expenditures were included in amounts receivable because they were considered to be advances to the marketing company for advertising and were wholly repayable once sales levels reached a certain contracted level. During the year-end audit, management and the audit committee met to review developments with regard to these amounts. This review led to a determination to expense a significant portion ($571,985) of these advances in the quarter ended March 31, 2006.
The loss for the quarter ended June 30, 2006 was $356,590 (2005: $367,368) and the loss per common share was $0.01 for both periods.
Financial Highlights
The net loss for the quarter was $356,590 (2005: $367,368). After adding back items not involving cash (including amortization, stock-based compensation), non-cash operating working capital items used $39,728 (2005: $361,877). In 2005 Advances to the Mexican marketing company increased by $232,319. These advances were charged against income as Product marketing costs in the fourth quarter ended March 31, 2006.
As a result of the above, operating activities used $228,202 (2005: $498,214) in cash during the three-months ended June 30, 2006.
Financing activities provided $244,424 (2005: $588,660) in cash flow. During the quarter amounts due to related parties increased $244,424 (200: $12,136). In 2005 the Company received $576,524 (net of Private Placement Finder^s Fee) through the issuance of Common Shares. There was no change in Share Capital in 2006.
BIOTECH HOLDINGS LTD.
FIRST QUARTER REPORT
June 30, 2006
Management^s Discussion and Analysis
Financial Highlights (continued)
In November 2005, the Company agreed to a private placement with a related party. The private placement, for the purchase of 984,666 common share units, was subject to the approval of the TSX Venture Exchange. Each unit included a common share and a warrant to purchase an additional common share at $0.16 per share until November 7, 2007. In January 2006 the TSX Venture Exchange approved this private placement but as at June 30, 2006 the shares had not been issued and the amount received ($118,160) has been included in amounts due to related parties. The shares are expected to be issued upon the resumption of trading of the Company shares on the TSX Venture Exchange.
Investing activities provided $Nil (2005: $46,731) in cash.
As a result cash increased $16,222 (2005: $137,177) in the three-month period. As at June 30, 2006, the working capital deficiency was $2,272,060 (June 30, 2005: $1,353,205).
Management plans to raise debt and equity capital on a private placement basis to finance the operating and capital requirements of the Company. It is management intention to continue using debt and equity to finance planned capital expansion and initial market development in Latin America and other markets and operations until such time as the Company operations are self-sustaining.
Liquidity and Capital Resources
The net loss for the quarter ended June 30, 2006 was $356,590 (2005: $367,368). After adding back items not involving cash (including amortization, stock-based compensation), non-cash operating working capital items provided $204,696 (2005: used $349,741). The non-cash operating working capital item with the most significant increase was $244,424 (2005: 12,136) in amounts due to related parties. In 2005 Advances to the Mexican Marketing company increased by $232,319. These advances were charged against income as Product marketing costs in the fourth quarter ended March 31, 2006.
As a result of the above, operating activities provided $16,222 (2005: used $486,078) in cash during the three-months ended June 30, 2006.
Financing activities provided $Nil (2005: $576,524) in cash flow mainly through the issuance of shares.
In November 2005, the Company agreed to a private placement with a related party. The private placement was subject to the approval of the TSX Venture Exchange and was for the purchase of 984,666 common shares at $0.12 per share. The purchase includes warrants to purchase 984,666 common shares at $0.16 per share until November 7, 2007. In January 2006 the TSX Venture Exchange approved this private placement but as at June 30, 2006 the shares were not issued and the amount received ($118,160) has been included in amounts due to related parties. The shares are expected to be issued upon the resumption of trading of the Company shares on the TSX Venture Exchange.
Investing activities provided $Nil (2005: $46,731) in cash.
As a result cash increased $16,222 (2005: $137,177) in the three month period. As at June 30, 2006, the working capital deficiency was $2,272,060 (June 30, 2005: $1,353,205).
Management plans to raise debt and equity capital on a private placement basis to finance the operating and capital requirements of the Company. It is management intention to continue using debt and equity to finance planned capital expansion and initial market development in Latin America and other markets and operations until such time as the Company operations are self-sustaining. Shareholders^ deficiency increased from $1,757,499 as at March 31, 2006 to $2,073,954 as at June 30, 2006.
BIOTECH HOLDINGS LTD.
FIRST QUARTER REPORT
June 30, 2006
Management^s Discussion and Analysis
Quarterly Comparison
The following table highlights the Company quarterly results from operations for the current and last two fiscal years:
Quarter Ended | June 30, 06 | Sept 30, 06 | Dec 31, 06 | Mar 31, 07 | Total Year | |
Revenues | $ 48,621 | $ 48,621 | ||||
Cost of Sales | 23,897 | 23,897 | ||||
Gross Profit | 24,724 | 24,724 | ||||
General, Administrative | ||||||
and Selling Expenses | 126,112 | 126,112 | ||||
Amortization | 127,981 | 127,981 | ||||
Product Marketing Costs | 34,710 | 34,710 | ||||
Professional Fees | 14,767 | 14,767 | ||||
Interest Expense | 16,670 | 16,670 | ||||
Office rent, utilities & Maintenance | 15,084 | 15,084 | ||||
Stock-based compensation | 40,135 | 40,135 | ||||
Foreign Exchange | 5,854 | 5,854 | ||||
Loss from Operations | (356,590) | (356,590) | ||||
Profit (Loss) from Discontinued Operations | 0 | 0 | ||||
Loss for the period | (356,590) | (356,590) | ||||
Outstanding Common Shares | 92,229,512 | 92,229,512 | ||||
Loss per share | (0.01) | (0.01) | ||||
Quarter Ended | June 30, 05* | Sept 30, 05* | Dec 31, 05* | Mar 31, 06 | Total Year | |
Revenues | $ 123,411 | $ 211,654 | $ 119,540 | $ 28,235 | $ 482,840 | |
Cost of Sales | 40,626 | 39,994 | 38,446 | 10,221 | 129,287 | |
Gross Profit | 80,785 | 171,660 | 81,094 | 18,014 | 353,553 | |
General, Administrative | ||||||
and Selling Expenses | 171,585 | 169,679 | 162,831 | 211,061 | 715,156 | |
Amortization | 152,480 | 152,480 | 152,481 | 152,671 | 610,112 | |
Product Marketing Costs | 0 | 0 | 0 | 571,985 | 571,985 | |
Professional Fees | 27,058 | 692 | 32,372 | 4,606 | 64,728 | |
Interest Expense | 13,989 | 14,318 | 14,144 | 18,345 | 60,796 | |
Stock-based compensation | 74,610 | 74,610 | 83,695 | 50,629 | 283,544 | |
Foreign Exchange | 6,490 | 56,944 | (4,937) | 1,604 | 60,101 | |
Loss before undernoted items | (363,427) | (297,063) | (359,492) | (992,887) | (2,012,869) | |
Non-controlling interest share | (17,165) | 17,165 | 0 | 0 | 0 | |
Profit (Loss) from Discontinued Operations | 13,224 | 0 | 0 | 63,000 | 76,224 | |
Loss for the period | (367,368) | (279,898) | (359,492) | (929,887) | (1,936,645) | |
Outstanding Common Shares | 92,229,512 | 92,229,512 | 92,229,512 | 92,229,512 | 92,229,512 | |
Loss per share | (0.01) | (0.00) | (0.00) | (0.01) | (0.02) | |
Quarter Ended | June 30, 04 | Sept 30, 04 | Dec 31, 04 | Mar 31, 05 | Total Year | |
Revenues | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | |
General, Administrative | ||||||
and Selling Expenses | 162,065 | 160,301 | 164,638 | 156,657 | 643,661 | |
Amortization | 152,983 | 154,131 | 152,191 | 153,125 | 612,430 | |
Professional Fees | 2,453 | 6,749 | 25,701 | 6,625 | 41,528 | |
Interest Expense | 16,890 | 17,062 | 15,817 | 21,236 | 71,005 | |
Stock-based compensation | 0 | 65,250 | 26,344 | 294,910 | 386,504 | |
Loss from continuing operations | (334,391) | (403,493) | (384,691) | (632,553) | (1,755,128) | |
Profit (Loss) from Discontinued Operations | 0 | 0 | 0 | 239,057 | 239,057 | |
Loss for the period | (334,391) | (403,493) | (384,691) | (393,496) | (1,516,071) | |
Outstanding Common Shares at period end | 87,935,219 | 88,209,719 | 90,034,310 | 90,034,310 | 90,034,310 | |
Loss per share | (0.00) | (0.01) | (0.00) | (0.01) | (0.02) |
*The quarters of June 30, September 30, and December 30 2005 have been restated to reflect the year-end reclassification of private placement finders fee as a reduction of contributed surplus.
BIOTECH HOLDINGS LTD.
FIRST QUARTER REPORT
June 30, 2006
Management^s Discussion and Analysis
Discussion on the Quarterly Comparison Chart
Revenues from the sale of Sucanon in the year ended March 31, 2006 were $482,840, which resulted in a Gross Profit of $353,553. There were no revenues in the same period ended March 31, 2005. Revenues showed significant growth in the first 6 months of fiscal 2006. There was a decline in quarterly revenues in the following 3 quarters. The main reasons for this trend were:
The trend to declining revenues was arrested in the first quarter: product marketing efforts increased in the quarter ended June 30, 2006 and, as a result, revenues increased from $28,235 in the quarter ended March 31, 2006 to $48,621 in the quarter ended June 30, 2006.
Operating expenses for the year ended March 31, 2006 totaled $2,366,422 representing a $611,294 (34.8%) increase from the $1,755,128 expenses incurred in the year ended March 31, 2005. The expense categories with significant increases included:
c. General, administrative and selling expenses increased from $438,704 to $658,529 ($219,825 or 50.1%) in the year. The Mexican office expenses increased by $98,721 (the Mexican office only operated for part of the prior year). Salaries and benefits increased by $38,890 and Communication and travel expenses increased by $22,874.
Quarterly operating costs for the 9 quarters presented averaged $500,300. The operating costs for the quarters ended March 31, 2005 and March 31, 2006 were significantly higher than this average. Stock-based compensation expenses of $294,910 in the quarter ended March 31, 2005 and $571,985 in Product Marketing Costs in the quarter ended March 31, 2006 accounted for the majority of the above-average operating costs in those quarters
Related party transactions
Amounts paid to related parties were based on exchange amounts which represented the amounts agreed upon by the related parties. No cash compensation is paid to directors in their capacity as directors. Amounts paid or payable to related parties include:
Management fees paid and
accrued to an officer $ 36,000
Salaries & Benefits $ 44,411
Interest accrued on Notes Payable
to related parties $ 16,670
Services provided by Companies
controlled by Directors $ 25,090
BIOTECH HOLDINGS LTD.
FIRST QUARTER REPORT
June 30, 2006
Management^s Discussion and Analysis
Related Party Transactions (continued)
Ongoing related party associations:
The Company has ongoing relationships with the following related parties. The following related parties are controlled by Mr. Robert Rieveley and his spouse, Cheryl Rieveley. These entities perform the following services to the Company and are party to the following agreements with the Company:
Secured Debt controlled by Mr. Robert Rieveley and his spouse, Cheryl Rieveley
The following notes bear interest at the rate of 8% per annum compounded annually and due on demand. They are collateralized by a General Security Agreement providing a charge over the assets of the Company:
June 30, 2006 | |
R Rieveley & Associates | $ 511,449 |
Wenroth Limited ("Wenroth") | 14,586 |
InReg Corporation ("InReg") | 104,039 |
Allburg Holdings ("Allburg") | 126,369 |
The General Security Agreements mentioned above have been registered with the Personal Property Security Registry in Victoria, B.C. Once the respective loans are paid in full the registration becomes null and void.
Transactions with Secured Creditors
In addition to interest charged on the above-mentioned notes, the Company had the following transactions with the secured creditors:
The Company retains the services of Mr. Rieveley through an employment agreement with R Rieveley & Associates. Management Fees paid to R Rieveley and Associates in the 3 months ended June 30, 2006 amounted to $36,000. During the 3 months ended June 30, 2006, R Rieveley & Associates advanced $220,821 to the Company.
In November 2005, the Company agreed to a private placement with R Rieveley and Associates. The private placement, for the purchase of 984,666 common share units, was subject to the approval of the TSX Venture Exchange. Each unit included a common share and a warrant to purchase an additional common share at $0.16 per share until November 7, 2007. In January 2006 the TSX Venture Exchange approved this private placement but as at June 30, 2006 the shares had not been issued and the amount received ($118,160) has been included in amounts due to related parties. The shares are expected to be issued upon the resumption of trading of the Company shares on the TSX Venture Exchange. The consideration received is non-interest bearing and secured by a general security agreement.
The Company owns 75% of Smith Rothe Pharmaceutical Inc. ("Smith Rothe"). Smith Rothe has been granted an exclusive license to sub-contract the manufacture and marketing of the Company Type II diabetes drug Sucanon make claims and to use all patent rights in countries outside Oriental Asia. The 25% non-controlling interest of Smith Rothe is held by Allburg and the 25% amount earned by the non-controlling interest will be reflected as single line items on both the Consolidated Balance Sheet and Consolidated Statements of Operations once marketing profits are realized.
BIOTECH HOLDINGS LTD.
FIRST QUARTER REPORT
June 30, 2006
Management^s Discussion and Analysis
Related Party Transactions (continued)
Other companies controlled by Mr. Robert Rieveley and his spouse, Cheryl Rieveley
Notes payable to RCAR Investment Ltd., are unsecured, bear interest at the rate of 8% per annum compounded annually and due on demand. As of June 30, 2006 the Company owed RCAR $281,821.
Sucanon is manufactured on behalf of the Company by a private company controlled by R. Rieveley. The manufacturing process is performed by employees of the Company. The private company transfers Sucanon to the Company at cost and receives no profit for this manufacturing operation. The Company uses this private company to maintain confidentiality regarding the manufacturing process for Sucanon. As of June 30, 2006, the Company owed the private company $8,253
First Choice Communications provides the Company with office space and computer services. Expenses paid to this company for services in the 3 months ended June 30, 2006 were $16,057.
Penne Investments Services Inc. ("Penne") provides financing to the Company via loans. As of June 30, 2006 the Company had no amounts owing to Penne.
Outstanding Share Data
The Company is authorized to issue an unlimited number of Series Convertible Preferred shares and common shares without par value. The preferred shares are voting and are convertible into common shares on a 1:1 basis. They have a cumulative cash dividend of 8% of the original amount contributed plus accrued interest. On June 30, 2006 there were 92,229,512 common and 13,806,907 preferred shares issued and outstanding.
Stock Options
Stock Options Exercised in the Period
No stock options were exercised during the quarter ended June 30, 2006.
Stock Options Granted in the Period
In June 2006, the Board of Directors replaced 896,000 stock options exercisable at $0.25 per share which expired on January 2, 2006, with new stock options exercisable at $0.16 per share. The replacement options vest on October 22, 2006 and expire on June 22, 2008. A total of 560,000 of these options were granted to Directors and Officers of the Company and the remaining 336,000 were granted to Consultants to the Company.
The Board of Directors also replaced 545,000 stock options exercisable at $0.55 per share which expired or were cancelled by March 24, 2006 with new stock options exercisable at $0.10 per share. These replacement options will vest October 22, 2006 and expire on June 22, 2008. A total of 470,000 of these options were granted to directors and officers and 75,000 were granted to consultants to the company.
On June 26, 2006, Mr. Ross Wilmot was appointed as a director of the Company. With this appointment, Mr. Wilmot was granted 300,000 share options exercisable at $0.10 per share, vesting October 26, 2006 and expiring June 25, 2008.
The stock options described above comply with the Stock Option Plan approved by the shareholders on September 30, 2005 and are subject to the approval of the TSX Venture Exchange.
Stock options and warrants outstanding as at June 30, 2006:
Total Employees
Exercise Price and expiry date Number Directors & Consultants
Officers
$0.54 Aug 11, 2006 75,000 75,000 0
$0.66 Aug 26, 2006 150,000 0 150,000
$0.55 Mar 24, 2007 700,000 600,000 100,000
$0.55 Mar 24, 2008 1,190,000 1,060,000 130,000
$0.135 Feb 22, 2008 300,000 300,000 0
$0.16 Jun 22, 2008 896,000 560,000 336,000
$0.10 Jun 22, 2008 545,000 470,000 75,000
$0.10 Jun 25, 2008 300,000 300,000 0
Outstanding as at June 30, 20064,156,000 3,365,000 791,000
BIOTECH HOLDINGS LTD.
FIRST QUARTER REPORT
June 30, 2006
Management^s Discussion and Analysis
Related Party Transactions (continued)
Stock options (continued)
A breakdown of outstanding options as at June 30, 2006 to Directors and Officers was as follows:
Grant Date | 24-Nov-04 | 24-Nov-04 | 22-Feb-06 | 23-Jun-06 | 23-Jun-06 | 26-Jun-06 | ||
Exercise Date | 24-Apr-06 | 24-Apr-07 | 22-Jun-06 | 22-Oct-06 | 22-Oct-06 | 26-Oct-06 | ||
Expiry Date | 24-Mar-07 | 24-Mar-08 | 22-Feb-08 | 22-Jun-08 | 22-Jun-08 | 25-Jun-08 | ||
Option Price | $0.55 | $0.55 | $0.135 | $0.16 | $0.10 | $0.10 | Total | |
Cheryl Rieveley | Director | 90,000 | 120,000 | 0 | 90,000 | 70,000 | 0 | 370,000 |
Gale Belding | Director | 90,000 | 120,000 | 0 | 0 | 70,000 | 0 | 280,000 |
Johan de Rooy | Director | 70,000 | 100,000 | 0 | 90,000 | 50,000 | 0 | 310,000 |
Robert Rieveley | Director & C.E.O. | 200,000 | 500,000 | 0 | 190,000 | 150,000 | 0 | 1,040,000 |
Art Cowie | Director | 0 | 0 | 300,000 | 0 | 50,000 | 0 | 350,000 |
Ross Wilmot | Director | 0 | 0 | 0 | 0 | 0 | 300,000 | 300,000 |
Lorne Brown | C.F.O. | 50,000 | 60,000 | 0 | 190,000 | 40,000 | 0 | 340,000 |
TOTAL | 500,000 | 900,000 | 300,000 | 560,000 | 430,000 | 300,000 | 2,990,000 |
Private Placement and Warrants Granted and exercised in the period
No private placements or warrants were either granted or exercised during the quarter ended June 30, 2006.
In November 2005, the Company agreed to a private placement with a related party. The private placement was subject to the approval of the TSX Venture Exchange and was for the purchase of 984,666 common shares at $0.12 per share. The purchase includes warrants to purchase 984,666 common shares at $0.16 per share until November 7, 2007. In January 2006, the TSX Venture Exchange approved this private placement but as at June 30, 2006 the shares had not been issued and the amount received ($118,160) has been included in amounts due to related parties. The shares are expected to be issued upon the resumption of trading of the Company shares on the TSX Venture Exchange.
Outstanding Warrants to Purchase Common Shares as of June 30, 2006
Expiry Date | Exercise Price | Total Outstanding | Directors & Officers | Other |
December 16, 2006 | $0.550 | 1,528,480 | 480,000 | 1,048,480 |
October 6, 2006 | $0.400 ($0.33 USD) | 2,020,202 | 2,020,202 | 0 |
TOTAL | 3,548,682 | 2,500,202 | 1,048,480 |
Recent Developments
The Company has been suspended from trading since December 6, 2005. During the period of suspension, sales of the Company Sucanon diabetes medication continued in Mexico through distributors set up by a Mexican marketing company. While sales have continued through these distributors, marketing efforts with regard to making direct contact with clinics, doctors and patients have been taken over increasingly by the Company management group in Mexico.
The Company has also been working to open markets for Sucanon in Latin America beyond Mexico. In Argentina, the Company has selected a distributor for Sucanon. This distributor is in the process of preparing a submission to Argentina^s medical regulator. The time-frame for this regulatory submission is not known at this point and there is no assurance that a regulatory submission, in Argentina, if made, will lead to approval of Sucanon for the Argentine market. As Argentina and Mexico both belong to the Mercosur Agreement, under which pharmaceutical approval in one Mercosur country expedites approval in other Mercosur countries, the Company believes that a regulatory approval in Argentina is likely. The costs of making the application are borne by the distributor.
The Company has also started discussions with a potential distributor for the United Arab Emirates. There is no assurance that sales in this market will occur or will be material. The Company has been advised that no regulatory approval is necessary for the sale of Sucanon in this market.
BIOTECH HOLDINGS LTD.
FIRST QUARTER REPORT
June 30, 2006
Management^s Discussion and Analysis
Other MD&A Requirements
Directors as at June 30, 2006:
Robert B. Rieveley, C.E.O.
Gale V. Belding
Art Cowie(1)
Johan de Rooy, FCA(1)
Cheryl Rieveley
Ross Wilmot(1)
(1)Independent Director and member of the Audit Committee
Officers as at June 30, 2006:
Robert B Rieveley, Chief Executive Officer
Lorne D. Brown, Chief Financial Officer
Additional Information
Additional information relating to the Company may be obtained from the System for Electronic Document analysis and Retrieval ("SEDAR"), which may be accessed at www.sedar.com.
